Future Market Insights (FMI)’ updated report on the asthma treatment market highlights several opportunities and growth prospects for the coming decade. As per the report, the asthma treatment market is set to surge from US$ 28.0 billion in 2024 and US$ 46.0 billion by 2034. The report reflects a robust CAGR of 5.1% between 2024 and 2034, inferring strong market growth.
| Attributes | Key Insights |
|---|---|
| Global Asthma Treatment Market Size (2024E) | US$ 28.0 billion |
| Market Value (2034F) | US$ 46.0 billion |
| Value-based CAGR (2024 to 2034) | 5.1% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The increasing incidence of asthma, growing knowledge about asthma medications, and advancements in asthma treatment choices are projected to spur market growth. The industry is further propelled by environmental factors such as air pollution, allergens, and lifestyle changes, which contribute to the surged prevalence of asthma worldwide.
Precision medicine is gaining traction in the asthma treatment industry as demand for individualized asthma medications increases. Mobile applications, smart inhalers, and wearable devices are improving tailored asthma therapy by allowing for real-time monitoring of symptoms, medication adherence, and lung function.
This accurate data gathering helps healthcare practitioners and professionals to understand each patient's asthma management better and offer appropriate treatment solutions.
Remote monitoring and telemedicine services are further estimated to enhance personalized treatment for patients in remote and underdeveloped areas. Pharmaceutical companies and research organizations are investing in innovating new drugs and therapies to meet the diverse needs of asthma patients globally.
Public health initiatives and awareness campaigns are further boosting market development. Urbanization, industrialization, genetic susceptibility, and family history of asthma are set to contribute to mounting asthma prevalence, creating an environment favorable for market growth.
From 2019 to 2023, bronchodilators such as theophylline and beta-agonists were primarily considered as asthma treatments, providing relief from symptoms. During 2019 and 2023, the market grew at a CAGR of 6.8%. Development in genetics and biomarker research has enabled personalized asthma treatment, optimizing its efficacy and minimizing side effects.
Digital health technologies, such as asthma management mobile apps, smart inhalers, and telemedicine services, further enabled better monitoring of asthma symptoms, medication adherence, and remote patient management.
Principal Consultant
Smart inhalers, smartphone applications, and telemedicine are improving asthma therapy by allowing for remote monitoring, medication adherence, and increased patient awareness and education. Preventive methods, such as environmental trigger reduction and lifestyle modifications aimed at reducing exacerbations and improving long-term treatment results, are set to fuel the market development.
Combination inhalers with bronchodilators and corticosteroids are gaining traction in asthma management due to their ease of use and improved patient outcomes. Healthcare policies, reimbursement structures, and value-based care initiatives are set to fuel asthma treatment adoption globally.
Leading companies and producers are focusing on developing novel therapeutic targets, drug delivery systems, and alternative treatments, propelling market development. The shift toward patient-centric care models, self-management education, and empowerment is gaining momentum in several emerging markets.
The section below highlights the projected growth rates of leading countries. Among these, South Korea is set to remain a highly lucrative market, exhibiting a CAGR of 7.2%. Japan and the United Kingdom are estimated to follow with CAGRs of 6.8% and 6.3%, respectively.
| Countries | Projected CAGR (2024 to 2034) |
|---|---|
| United States | 5.4% |
| United Kingdom | 6.3% |
| China | 5.9% |
| South Korea | 7.2% |
| Japan | 6.8% |
The asthma treatment industry can be observed in the subsequent tables, which focus on the leading economies, consisting of South Korea, Japan, the United Kingdom, China, and the United States. A comprehensive evaluation demonstrates that the United States has enormous potential for growth in the market.
| Countries | Market Values (2034) |
|---|---|
| United States | US$ 8.3 billion |
| United Kingdom | US$ 1.9 billion |
| China | US$ 7.3 billion |
| South Korea | US$ 3.0 billion |
| Japan | US$ 5.2 billion |
The United States is set to dominate the market by 2034, surging at a CAGR of 5.4%. Asthma, a common non-communicable disease in the United States, accounts for around 73% of outpatient clinic visits, creating a wide target population for effective asthma therapeutics.
Established healthcare infrastructure and increasing asthma prevalence in the United States are the key factors propelling market growth. The United States is further projected to grow significantly due to improved government reforms, a rising geriatric population, increasing healthcare expenditure, and growing consumer awareness about lung diseases.
By 2034, China is projected to grow substantially at a CAGR of 5.9%. Government initiatives, subsidies, and reimbursement policies to improve treatment quality, promote evidence-based practices, and reduce healthcare inconsistencies are influencing asthma therapy adoption in China.
Leading companies in China are focusing on research & development to innovate new therapeutic treatments, improve drug delivery systems, and understand asthma pathophysiology to reach wider customers.
The competitive asthma care market in China encourages innovation through collaborations and partnerships between industry stakeholders, academia, and patient advocacy groups.
Japan is projected to propel due to factors such as high asthma prevalence, increased consumer awareness, and innovations in treatment options. Developments in biologic medications and targeted therapies, which offer improved efficacy and fewer side effects, are estimated to fuel growth in the market.
The market in Japan is further anticipated to be influenced by increased FDA endorsements and key market strategies such as collaboration, mergers, and partnerships among local and international companies. The market's development is projected to be accelerated by key players intensifying their geographical presence in emerging nations. By 2034, Japan is projected to reach US$ 5.2 billion.
South Korea is home to several leading pharmaceutical companies specializing in asthma treatment, medication development, and manufacturing. These companies contribute to innovative asthma management therapies, propelling market growth in South Korea. South Korea is projected to reach a market valuation of US$ 3.0 billion in 2034.
South Korea's regulatory framework and favorable government reimbursement system encourage asthma treatment adoption, providing patients with a wide range of treatment options and fueling market reach.
South Korea is a leading center for asthma research and clinical trials, involving academic institutions, research centers, and healthcare organizations to develop new treatment methods.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The segmented market analysis is included in the subsequent section. Based on comprehensive studies, the inhaler segment is dominating the product category. Likewise, the oral segment is commanding the route of administration category.
| Segment | Value CAGR (2024 to 2034) |
|---|---|
| Inhalers (Product) | 4.8% |
| Oral (Route of Administration) | 4.6% |
The inhalers segment, with its reliability, versatility, portability, and cost-effectiveness, is projected to lead the product segment by 2034. The growing prevalence of asthma and COPD, along with the need for emergency treatment alternatives, is propelling the segment’s growth.
The development of progressive products, such as Trelegy Ellipta, a triple therapy inhaler approved in the United States, is also projected to fuel segment growth. Based on product, the inhaler segment is set to surge at a CAGR of 4.8% by 2034.
Based on the route of administration, the oral segment is set to rise at 4.6% CAGR by 2034. The segment is projected to witness a leading growth rate from 2024 to 2034 due to its convenience and efficacy.
Oral medications, taken by mouth and absorbed through the digestive system, are well-preferred and easy to use, making them popular among patients and healthcare providers. The convenience, effectiveness, and versatility of the oral route of administration make the segment a valuable tool for managing asthma, boosting the segment's growth.
Leading pharmaceutical companies are inclined toward research & development to surge their market reach while emerging biotech companies innovate targeted treatments to uphold their positions. Market growth relies on regulatory adherence, diagnostic research, strategic partnerships, and adapting to evolving consumer tastes.
For instance
The market is set to reach US$ 28.0 billion in 2024.
Demand for asthma treatment is slated to rise at a 5.1% CAGR by 2034.
The market is set to reach US$ 46.0 billion in 2034.
Teva Pharmaceutical Industries Ltd, GSK plc, Merck & Co.Inc, and AstraZeneca are the key players.
The inhaler segment is estimated to hold a significant market share in 2024.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and their Roles 3.5.1.1. Manufacturer 3.5.1.2. Mid-Level Participants (Traders) 3.5.1.3. Wholesalers and Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyer’s 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Wholesalers and Distributors 3.7.3. Retailers 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Production and Consumption Statistics 3.12. Import and Export Statistics 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034 4.1. Historical Market Size Value (US$ million) & Volume (Units) Analysis, 2019 to 2023 4.2. Current and Future Market Size Value (US$ million) & Volume (Units) Projections, 2024 to 2034 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ million) & Volume (Units) Analysis By Drug Class, 2019 to 2023 5.3. Current and Future Market Size Value (US$ million) & Volume (Units) Analysis and Forecast By Drug Class, 2024 to 2034 5.3.1. Anti-inflammatory 5.3.2. Bronchodilators 5.3.3. Combination Therapy 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2019 to 2023 5.5. Absolute $ Opportunity Analysis By Drug Class, 2024 to 2034 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ million) & Volume (Units) Analysis By Product, 2019 to 2023 6.3. Current and Future Market Size Value (US$ million) & Volume (Units) Analysis and Forecast By Product, 2024 to 2034 6.3.1. Inhalers 6.3.1.1. Dry Powder 6.3.1.2. Metered Dose 6.3.1.3. Soft Mist 6.3.2. Nebulizers 6.4. Y-o-Y Growth Trend Analysis By Product, 2019 to 2023 6.5. Absolute $ Opportunity Analysis By Product, 2024 to 2034 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ million) & Volume (Units) Analysis By Route of Administration, 2019 to 2023 7.3. Current and Future Market Size Value (US$ million) & Volume (Units) Analysis and Forecast By Route of Administration, 2024 to 2034 7.3.1. Oral 7.3.2. Inhaled 7.3.3. Others 7.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2019 to 2023 7.5. Absolute $ Opportunity Analysis By Route of Administration, 2024 to 2034 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ million) & Volume (Units) Analysis By Region, 2019 to 2023 8.3. Current Market Size Value (US$ million) & Volume (Units) Analysis and Forecast By Region, 2024 to 2034 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. South Asia and Pacific 8.3.6. East Asia 8.3.7. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 9.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 9.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 9.2.1. By Country 9.2.1.1. United States 9.2.1.2. Canada 9.2.2. By Drug Class 9.2.3. By Product 9.2.4. By Route of Administration 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Class 9.3.3. By Product 9.3.4. By Route of Administration 9.4. Key Takeaways 10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 10.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 10.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug Class 10.2.3. By Product 10.2.4. By Route of Administration 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class 10.3.3. By Product 10.3.4. By Route of Administration 10.4. Key Takeaways 11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 11.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 11.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Western Europe 11.2.2. By Drug Class 11.2.3. By Product 11.2.4. By Route of Administration 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By Product 11.3.4. By Route of Administration 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 12.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 12.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Czech Republic 12.2.1.4. Romania 12.2.1.5. Rest of Eastern Europe 12.2.2. By Drug Class 12.2.3. By Product 12.2.4. By Route of Administration 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By Product 12.3.4. By Route of Administration 12.4. Key Takeaways 13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 13.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 13.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Bangladesh 13.2.1.3. Australia 13.2.1.4. New Zealand 13.2.1.5. Rest of South Asia and Pacific 13.2.2. By Drug Class 13.2.3. By Product 13.2.4. By Route of Administration 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By Product 13.3.4. By Route of Administration 13.4. Key Takeaways 14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 14.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 14.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Drug Class 14.2.3. By Product 14.2.4. By Route of Administration 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Class 14.3.3. By Product 14.3.4. By Route of Administration 14.4. Key Takeaways 15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 15.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 15.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of Middle East and Africa 15.2.2. By Drug Class 15.2.3. By Product 15.2.4. By Route of Administration 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Class 15.3.3. By Product 15.3.4. By Route of Administration 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. United States 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2024 16.1.2.1. By Drug Class 16.1.2.2. By Product 16.1.2.3. By Route of Administration 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2024 16.2.2.1. By Drug Class 16.2.2.2. By Product 16.2.2.3. By Route of Administration 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2024 16.3.2.1. By Drug Class 16.3.2.2. By Product 16.3.2.3. By Route of Administration 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2024 16.4.2.1. By Drug Class 16.4.2.2. By Product 16.4.2.3. By Route of Administration 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2024 16.5.2.1. By Drug Class 16.5.2.2. By Product 16.5.2.3. By Route of Administration 16.6. United Kingdom 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2024 16.6.2.1. By Drug Class 16.6.2.2. By Product 16.6.2.3. By Route of Administration 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2024 16.7.2.1. By Drug Class 16.7.2.2. By Product 16.7.2.3. By Route of Administration 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2024 16.8.2.1. By Drug Class 16.8.2.2. By Product 16.8.2.3. By Route of Administration 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2024 16.9.2.1. By Drug Class 16.9.2.2. By Product 16.9.2.3. By Route of Administration 16.10. Poland 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2024 16.10.2.1. By Drug Class 16.10.2.2. By Product 16.10.2.3. By Route of Administration 16.11. Russia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2024 16.11.2.1. By Drug Class 16.11.2.2. By Product 16.11.2.3. By Route of Administration 16.12. Czech Republic 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2024 16.12.2.1. By Drug Class 16.12.2.2. By Product 16.12.2.3. By Route of Administration 16.13. Romania 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2024 16.13.2.1. By Drug Class 16.13.2.2. By Product 16.13.2.3. By Route of Administration 16.14. India 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2024 16.14.2.1. By Drug Class 16.14.2.2. By Product 16.14.2.3. By Route of Administration 16.15. Bangladesh 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2024 16.15.2.1. By Drug Class 16.15.2.2. By Product 16.15.2.3. By Route of Administration 16.16. Australia 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2024 16.16.2.1. By Drug Class 16.16.2.2. By Product 16.16.2.3. By Route of Administration 16.17. New Zealand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2024 16.17.2.1. By Drug Class 16.17.2.2. By Product 16.17.2.3. By Route of Administration 16.18. China 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2024 16.18.2.1. By Drug Class 16.18.2.2. By Product 16.18.2.3. By Route of Administration 16.19. Japan 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2024 16.19.2.1. By Drug Class 16.19.2.2. By Product 16.19.2.3. By Route of Administration 16.20. South Korea 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2024 16.20.2.1. By Drug Class 16.20.2.2. By Product 16.20.2.3. By Route of Administration 16.21. GCC Countries 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2024 16.21.2.1. By Drug Class 16.21.2.2. By Product 16.21.2.3. By Route of Administration 16.22. South Africa 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2024 16.22.2.1. By Drug Class 16.22.2.2. By Product 16.22.2.3. By Route of Administration 16.23. Israel 16.23.1. Pricing Analysis 16.23.2. Market Share Analysis, 2024 16.23.2.1. By Drug Class 16.23.2.2. By Product 16.23.2.3. By Route of Administration 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Drug Class 17.3.3. By Product 17.3.4. By Route of Administration 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Teva Pharmaceutical Industries Ltd. 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.1.5.2. Product Strategy 18.1.1.5.3. Channel Strategy 18.1.2. GSK plc 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.2.5.2. Product Strategy 18.1.2.5.3. Channel Strategy 18.1.3. Merck & Co., Inc. 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.3.5.2. Product Strategy 18.1.3.5.3. Channel Strategy 18.1.4. F. Hoffmann-La Roche Ltd 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.4.5.2. Product Strategy 18.1.4.5.3. Channel Strategy 18.1.5. AstraZeneca 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.5.5.2. Product Strategy 18.1.5.5.3. Channel Strategy 18.1.6. Boehringer Ingelheim International GmbH 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.6.5.2. Product Strategy 18.1.6.5.3. Channel Strategy 18.1.7. Sanofi. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.7.5.2. Product Strategy 18.1.7.5.3. Channel Strategy 18.1.8. Koninklijke Philips N.V. 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.8.5.2. Product Strategy 18.1.8.5.3. Channel Strategy 18.1.9. BD 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.9.5.2. Product Strategy 18.1.9.5.3. Channel Strategy 18.1.10. Covis Pharma 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 18.1.10.5.2. Product Strategy 18.1.10.5.3. Channel Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Asthma Treatment Market
